The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good results in this context, but no direct comparisons available of pharmacological balloonsversus second-generation DES.This prospective, multicenter randomized 189 patients with in-stent restenosis of conventional stents receiving pharmacological balloon or everolimusDES.The primary endpoint was angiographicat 9 months spotting a minimum lumen diameter significantly lower in the pharmacological balloon group versus DES (2.01 mm versus 2.36 mm respectively, p <0.001 ).Late lumen loss was small for both devices with a tendency to be higher with pharmacological balloon. Binary restenosis rates were low and comparable between them.While the minimal luminal diameter was smaller with pharmacological balloons this, at least in this study, did not result in more clinical events with the advantage of avoiding a double layer of the stent and reduce the need for dual antiplatelet therapy.
Fernando Alfonso
2013-10-30
Original title: RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis
